MK-0354

MK-0354 is a specific GPR109a receptor agonist with EC50 values of 1.65 μM and 1.08 μM for hGPR109a and mGPR109a, respectively. MK-0354 can be used in liver cancer research[1][2][3][4].

Product Specifications

CAS Number

[851776-28-8]

UNSPSC

12352005

Hazard Statement

H315-H319-H320

Target

GPR109A

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/MK-0354.html

Purity

99.73

Solubility

DMSO : ≥ 36 mg/mL

Smiles

C12=C(CCC2)C(C3=NN=NN3)=NN1

Molecular Formula

C7H8N6

Molecular Weight

176.18

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]Semple G, et al. 3- (1H-Tetrazol-5-yl) -1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354) : A Partial Agonist of the Nicotinic Acid Receptor, G-Protein Coupled Receptor 109a, with Antilipolytic but No Vasodilatory Activity in Mice. J. Med. Chem., 2008, 51 (16), pp 5101-5108|[2]Lai E1, et al. Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans. J Clin Lipidol. 2008 Oct;2 (5) :375-383.|[3]Walters RW, et al. beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest. 2009 May;119 (5) :1312-21. |[4]Yang Y, et al. Dietary vitamin B3 supplementation induces the antitumor immunity against liver cancer via biased GPR109A signaling in myeloid cell. Cell Rep Med. 2024 Sep 17;5 (9) :101718.